Clinical Outcomes of Cabozantinib in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma—Importance of Good Liver Function and Good Performance Status

SIMPLE SUMMARY: The combination of atezolizumab plus bevacizumab (Atz/Bev) is now widely used in clinical practice as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC). However, the established regimen for post-treatment after Atz/Bev is unknown. We investigated the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuzuya, Teiji, Kawabe, Naoto, Ariga, Mizuki, Ohno, Eizaburo, Funasaka, Kohei, Nagasaka, Mitsuo, Nakagawa, Yoshihito, Miyahara, Ryoji, Shibata, Tomoyuki, Takahara, Takeshi, Kato, Yutaro, Hirooka, Yoshiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251863/
https://www.ncbi.nlm.nih.gov/pubmed/37296914
http://dx.doi.org/10.3390/cancers15112952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251863/
https://www.ncbi.nlm.nih.gov/pubmed/37296914
http://dx.doi.org/10.3390/cancers15112952

Ejemplares similares